Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial

Abstract Objectives Currently, there are no approved treatments for early disease stages of COVID-19 and few strategies to prevent disease progression after infection with SARS-CoV-2. The objective of this study is to evaluate the safety and efficacy of convalescent plasma (CP) or camostat mesylate...

Descripció completa

Dades bibliogràfiques

Autors principals:	Verena Keitel, Björn Jensen, Torsten Feldt, Johannes C. Fischer, Johannes G. Bode, Christiane Matuschek, Edwin Bölke, Wilfried Budach, Christian Plettenberg, Kathrin Scheckenbach, Detlef Kindgen-Milles, Jörg Timm, Lisa Müller, Henrike Kolbe, Andreas Stöhr, Christian Calles, Andreas Hippe, Pablo Verde, Christoph D. Spinner, Jochen Schneider, Timo Wolf, Winfried V. Kern, Jacob Nattermann, Alexander Zoufaly, Christian Ohmann, Tom Luedde, RES-Q-HR Trial Team
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2021-05-01
Col·lecció:	Trials
Matèries:	COVID-19 Randomized controlled trial Protocol Convalescent plasma Camostat mesylate Antiviral therapy
Accés en línia:	https://doi.org/10.1186/s13063-021-05181-0
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!